Fierce Biotech June 20, 2024
Private equity dollars are flowing toward clinical trial sites as industry conditions demand larger site networks, PitchBook’s analysis of first quarter 2024 deal activity shows.
“Clinical trial sites are undoubtedly the hottest category of pharma services as previously [physician practice management]-focused firms pivot into the life sciences category closest to their historical area of expertise,” the report’s authors wrote. Notable examples of this trend include the buyout of Worldwide Clinical Trials by Kohlberg & Co. and VSS Capital Partners’ investment in Eximia Research Network, both of which closed in late 2023.
Given that the trial site niche is still fragmented, there’s plenty of room for M&A activity, according to the analysis. Contract research organizations (CROs) are hopping on the opportunity,...
Today's Sponsors
Today's Sponsor